TY - CHAP
T1 - Parkinson's disease and Covid-19
T2 - The effect and use of telemedicine
AU - Podlewska, Aleksandra M.
AU - van Wamelen, Daniel J.
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/1
Y1 - 2022/1
N2 - As a result of the Coronavirus Disease 2019 (Covid-19) pandemic the use of telemedicine and remote assessments for patients has increased exponentially, enabling healthcare professionals to reduce the need for in-person clinical visits and, consequently, reduce the exposure to the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This development has been aided by increased guidance on digital health technologies and cybersecurity measures, as well as reimbursement options within healthcare systems. Having been able to continue to connect with people with Parkinson's Disease (PwP, PD) has been crucial, since many saw their symptoms worsen over the pandemic. Inspite of the success of telemedicine, sometimes even enabling delivery of treatment and research, further validation and a unified framework are necessary to measure the true benefit to both clinical outcomes and health economics. Moreover, the use of telemedicine seems to have been biased towards people from a white background, those with higher education, and reliable internet connections. As such, efforts should be pursued by being inclusive of all PwP, regardless of geographical area and ethnic background. In this chapter, we describe the effect he Covid-19 pandemic has had on the use of telemedicine for care and research in people with PD, the limiting factors for further rollout, and how telemedicine might develop further.
AB - As a result of the Coronavirus Disease 2019 (Covid-19) pandemic the use of telemedicine and remote assessments for patients has increased exponentially, enabling healthcare professionals to reduce the need for in-person clinical visits and, consequently, reduce the exposure to the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This development has been aided by increased guidance on digital health technologies and cybersecurity measures, as well as reimbursement options within healthcare systems. Having been able to continue to connect with people with Parkinson's Disease (PwP, PD) has been crucial, since many saw their symptoms worsen over the pandemic. Inspite of the success of telemedicine, sometimes even enabling delivery of treatment and research, further validation and a unified framework are necessary to measure the true benefit to both clinical outcomes and health economics. Moreover, the use of telemedicine seems to have been biased towards people from a white background, those with higher education, and reliable internet connections. As such, efforts should be pursued by being inclusive of all PwP, regardless of geographical area and ethnic background. In this chapter, we describe the effect he Covid-19 pandemic has had on the use of telemedicine for care and research in people with PD, the limiting factors for further rollout, and how telemedicine might develop further.
KW - Covid-19
KW - Parkinson's disease
KW - SARS-CoV-2
KW - Telemedicine
KW - Wearables
UR - http://www.scopus.com/inward/record.url?scp=85134176949&partnerID=8YFLogxK
U2 - 10.1016/bs.irn.2022.04.002
DO - 10.1016/bs.irn.2022.04.002
M3 - Chapter
AN - SCOPUS:85134176949
SN - 9780323991735
T3 - International Review of Neurobiology
SP - 263
EP - 281
BT - Covid-19 and Parkinsonism
A2 - Chaudhuri, K Ray
A2 - Rodríguez-Violante, Mayela
A2 - Antonini, Angelo
A2 - Boura, Iro
A2 - Boura, Iro
PB - ACADEMIC PRESS INC
ER -
